Clinical trials recruiting in Prato, Italy

Phase breakdown

Conditions recruiting in Prato, Italy

Recruiting trials in Prato, Italy

• A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
  NCT06931717 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
  NCT06492616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
  NCT07287098 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female
• A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
  NCT06926868 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
  NCT06994377 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase
  NCT06894173 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female)
• FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
  NCT06733038 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female)
• Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
  NCT06897644 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
  NCT06044623 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female)
• Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
  NCT07085767 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)
• To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
  NCT04660435 · Phase: Not specified · Ages: No age limits stated · Sex: Female
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
  NCT05950945 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female)

Common questions

How many clinical trials are recruiting in Prato, Italy?

14 recruiting trials have at least one study site in Prato, Italy.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.